RxDoctor Payments Data

Frank Malensek, MD

Internal Medicine · Birmingham, ALNPI 1598739500

Payments from drug & device makers

$1,450in general payments, 2019–2025

Across 94 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$372
  • AbbVie$243
  • Pfizer$199
  • Merck$108
  • Amgen$83
  • Bayer$74
  • plus $371 from 17 others

What the payments were for

  • Food & beverage$1,43599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,450 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$405,365
Medicare patients
357
Services billed
32,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$183,407
MounjaroTirzepatide155$163,370
RybelsusSemaglutide67$109,626
JanuviaSitagliptin Phosphate123$106,562
OzempicSemaglutide91$101,699
MyrbetriqMirabegron145$80,586
FarxigaDapagliflozin Propanediol74$59,356
JardianceEmpagliflozin33$34,804
GemtesaVibegron29$27,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,223
LinzessLinaclotide31$22,414
Teriparatide11$20,891
EntrestoSacubitril/Valsartan25$17,816
Breo ElliptaFluticasone/Vilanterol38$15,349
XareltoRivaroxaban15$15,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$372$211,326158 claims
PfizerEliquis$199$183,407208 claims
Lilly USA, LLCMounjaro$69$163,370155 claims
MerckJanuvia, Lagevrio (Eua)$108$114,458136 claims
Astellas Pharma US IncMyrbetriq$19$80,586145 claims
AstraZenecaFarxiga$13$59,35674 claims
GSKTrelegy Ellipta, Breo Ellipta$17$40,57171 claims
AbbVieLinzess$243$22,41431 claims
NovartisEntresto$13$17,81625 claims
Johnson & JohnsonXarelto$19$15,33015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →